ALX Oncology’s ALX148 Receives Two Fast Track Designations from FDA for the Treatment of Patients with Head and Neck Squamous Cell Carcinoma and Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
ALX Oncology won fast-track designation from the FDA for its drug ALX148 in the second-line treatment of patients with HER2-positive gastric cancer.
